tiprankstipranks
Eloxx Pharmaceuticals Inc (ELOX)
OTHER OTC:ELOX
Holding ELOX?
Track your performance easily

Eloxx Pharmaceuticals (ELOX) Income Statement

286 Followers

Eloxx Pharmaceuticals Income Statement

Last quarter (Q3 2023), Eloxx Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Eloxx Pharmaceuticals's net income was $-3.59M. See Eloxx Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 54.16M$ 34.42M$ 66.02M$ 33.45M$ 50.55M$ -47.56M
Operating Income
$ -19.29M$ -34.42M$ -66.02M$ -33.45M$ -50.55M$ -47.56M
Net Non Operating Interest Income Expense
$ 17.00K$ 1.68M$ -1.25M$ -1.07M$ -544.00K$ 608.00K
Other Income Expense
$ 93.00K$ 29.00K$ 709.00K$ 1.12M$ 319.00K$ -502.00K
Pretax Income
$ -20.48M$ -36.06M$ -66.73M$ -26.54M$ -50.87M$ -47.06M
Tax Provision
-----$ 122.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -20.48M$ -36.06M$ -66.73M$ -26.54M$ -50.82M$ -47.19M
Basic EPS
$ -22.59$ -16.65$ -38.15$ -0.86$ -1.34-
Diluted EPS
$ -22.46$ -16.65$ -38.15$ -0.86$ -1.34$ -58.00
Basic Average Shares
$ 9.29M$ 2.17M$ 1.75M$ 40.12M$ 38.06M$ 810.91K
Diluted Average Shares
$ 9.29M$ 2.17M$ 1.75M$ 40.12M$ 38.06M$ 813.53K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 54.16M$ 34.42M$ 66.02M$ 33.45M$ 50.55M$ -47.56M
Net Income From Continuing And Discontinued Operation
$ -20.48M$ -36.06M$ -66.73M$ -34.58M$ -50.87M$ -47.19M
Normalized Income
$ -10.93M$ -28.49M$ -53.72M---
Interest Expense
------
EBIT
$ -20.11M$ -34.12M$ -65.47M$ -33.17M$ -49.26M$ -47.07M
EBITDA
$ -19.23M$ -32.88M$ -64.51M$ -32.60M$ -48.47M$ -46.85M
Currency in USD

Eloxx Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis